Drug Profile
CIGB 814
Alternative Names: CIGB814Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class Anti-inflammatories; Antirheumatics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Cuba (SC, Injection)
- 31 Jan 2017 Center for Genetic Engineering and Biotechnology and Havana Ministry of Public Health, Cuba plan a phase II trial for Rheumatoid arthritis (Adjunctive treatment) in Cuba (SC) (RPCEC00000230)
- 24 Feb 2016 CIGB has patent protection for CIGB 814 in USA, Europe, Japan and Mexico